Novo Nordisk CEO explains decision to discontinue the long-acting insulin Levemir. He blamed pharmacy managers and health ...

For the millions of people living with diabetes or obesity, drugs like Ozempic and Wegovy can significantly improve their ...

Novo Nordisk CEO grilled over company's pricing for the diabetes drug Ozempic and the weight-loss drug Wegovy.

Novo Nordisk chief executive Lars Fruergaard Jørgensen was taken to task by US lawmakers over the price of the company's ...

Weight-loss drugs sell in Europe for a fraction of what they cost in the United States, a pattern that is typical for ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

The CEO of Novo Nordisk took questions for more than two hours during a Senate Health Committee hearing focused on addressing ...

WASHINGTON (TND) — The Senate Committee on Health, Education, Labor and Pensions held a hearing on Tuesday to discuss popular ...

The head of Ozempic manufacturer Novo Nordisk on Tuesday defended the high price of the company’s highly sought-after obesity and Type 2 diabetes drugs, blaming pharma middlemen ...

Novo Nordisk Chief Executive Lars Jorgensen challenged Medicare's new role negotiating prescription drug prices during his testimony before a Senate committee on the company's blockbuster diabetes and ...